Pharmaceutical formulation
US5849700A · kind A · utility
62Cited by
2References
15Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 2, 1995 |
| Grant date | Dec 15, 1998 |
| Priority date | — |
| Expiry date | Jun 2, 2015 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K38/27
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A pharmaceutical preparation comprising a growth hormone and histidine or a derivative of histidine as additive or buffering substance shows a very high stability against deamidation, oxidation and cleavage of peptide bonds. The stability of the product allows for the storing and shipment thereof in a lyophilized state or in the form of a dissolved or re-dissolved preparation at ambient temperature. Crystallization of growth hormone in the presence of histidine or a derivative thereof gives rise to a higher yield of crystals having a higher purity than known methods.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.